1068 related articles for article (PubMed ID: 24202392)
1. The quest to overcome resistance to EGFR-targeted therapies in cancer.
Chong CR; Jänne PA
Nat Med; 2013 Nov; 19(11):1389-400. PubMed ID: 24202392
[TBL] [Abstract][Full Text] [Related]
2. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.
Yamaoka T; Ohba M; Ohmori T
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29140271
[TBL] [Abstract][Full Text] [Related]
3. Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer.
Husain H; Scur M; Murtuza A; Bui N; Woodward B; Kurzrock R
Mol Cancer Ther; 2017 Feb; 16(2):265-272. PubMed ID: 28159915
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of resistance to EGFR targeted therapies.
Hrustanovic G; Lee BJ; Bivona TG
Cancer Biol Ther; 2013 Apr; 14(4):304-14. PubMed ID: 23358468
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
Dhomen NS; Mariadason J; Tebbutt N; Scott AM
Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.
Yu HA; Riely GJ; Lovly CM
Clin Cancer Res; 2014 Dec; 20(23):5898-907. PubMed ID: 25303979
[TBL] [Abstract][Full Text] [Related]
7. A Third Shot at EGFR: New Opportunities in Cancer Therapy.
Guardiola S; Varese M; Sánchez-Navarro M; Giralt E
Trends Pharmacol Sci; 2019 Dec; 40(12):941-955. PubMed ID: 31706618
[TBL] [Abstract][Full Text] [Related]
8. EGFR-TKIs resistance via EGFR-independent signaling pathways.
Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
Wykosky J; Fenton T; Furnari F; Cavenee WK
Chin J Cancer; 2011 Jan; 30(1):5-12. PubMed ID: 21192840
[TBL] [Abstract][Full Text] [Related]
10. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.
Chen LF; Cohen EE; Grandis JR
Clin Cancer Res; 2010 May; 16(9):2489-95. PubMed ID: 20406834
[TBL] [Abstract][Full Text] [Related]
11. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.
Blakely CM; Bivona TG
Cancer Discov; 2012 Oct; 2(10):872-5. PubMed ID: 23071030
[TBL] [Abstract][Full Text] [Related]
12. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.
Yano S; Takeuchi S; Nakagawa T; Yamada T
Cancer Sci; 2012 Jul; 103(7):1189-94. PubMed ID: 22435662
[TBL] [Abstract][Full Text] [Related]
13. Modeling therapy resistance via the EGFR signaling pathway.
Plattner C; Hackl H
FEBS J; 2019 Apr; 286(7):1284-1286. PubMed ID: 30892828
[TBL] [Abstract][Full Text] [Related]
14. Highly active antitumor therapy (HAATT) for epidermal growth factor receptor-mutant lung cancer.
Chmielecki J; Pao W
Clin Cancer Res; 2010 Nov; 16(22):5371-3. PubMed ID: 21062927
[TBL] [Abstract][Full Text] [Related]
15. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W
Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS; Kobayashi S; Costa DB
Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
[TBL] [Abstract][Full Text] [Related]
17. Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.
Boeckx C; Baay M; Wouters A; Specenier P; Vermorken JB; Peeters M; Lardon F
Oncologist; 2013; 18(7):850-64. PubMed ID: 23821327
[TBL] [Abstract][Full Text] [Related]
18. New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer.
Zhou Y; Takahashi JI; Sakurai H
Biol Pharm Bull; 2024; 47(5):895-903. PubMed ID: 38692865
[TBL] [Abstract][Full Text] [Related]
19. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
[TBL] [Abstract][Full Text] [Related]
20. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]